Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome (TEAM-DS)

Funding: R33 HD100934 (NICHD)
PIs: Anna Esbensen, Ph.D.& Tanya Froehlich, MD
CCHMC Collaborators: Julia Anixt, MD.; Jeff Epstein, Ph.D.; Kelly Kamimura-Nishimura, MD.; David Spar, MD

Despite a higher risk of Attention Deficit Hyperactivity Disorder (ADHD) among children with Down syndrome (DS), rates of stimulant medication treatment are disproportionately low. We are conducting the first randomized clinical trial (RCT) of stimulant medication in children with DS+ADHD to provide evidence regarding the short- and long-term safety and efficacy of stimulant use in children with DS+ADHD, both with and without CHD. All children enrolled in the study will complete a comprehensive assessment battery evaluating ADHD diagnostic criteria as well as behavioral, cognitive, academic, and functional impairments.

• Aim #1: To determine the efficacy of methylphenidate treatment in remediating behavioral, cognitive, and functional impairments in children with DS+ADHD.

• Aim #2: To assess the short- and long-term safety of stimulant treatment in children with DS+ADHD, with a specific focus on cardiac safety.

• Aim #3: Explore moderators (e.g., IQ, ADHD subtype, executive functioning (EF), comorbid internalizing disorders, CHD) of MPH response and side effects.